Updates on the production of therapeutic antibodies using human hybridoma technique

Xenia A. Glukhova, Olga V. Prusakova, Julia A. Trizna, Michael M. Zaripov, Gaida V. Afanas’Eva, Anatoly S. Glukhov, Rimma A. Poltavtseva, Alexei A. Ivanov, Marco Avila-Rodriguez, George E. Barreto, Gjumrakch Aliev, Igor P. Beletsky

Research output: Contribution to journalArticlepeer-review

Abstract

Therapeutic antibodies are implicated into the very promising and fast growing area of pharmaceutics. Human hybridoma technology, allowing generation of natural human antibodies in a native form, seems to be the most direct way that require no additional modifications for production of therapeutic antibodies. However, technical difficulties in human hybridoma creation discovered in the 80s of the last century have switched the mainstream therapeutic antibody development into new directions like display and transgenic mice techniques. These approaches have provided remarkable achievements in antibody engineering within last 15 years, but also revealed other limitations. Thus, it is time to turn back to forgotten human hybridoma technology. In this review, we describe new advances in all components of human hybridoma technology and discuss challenges in generating novel therapeutic mABs based on hybridoma technologies.

Original languageEnglish
Pages (from-to)870-878
Number of pages9
JournalCurrent Pharmaceutical Design
Volume22
Issue number7
DOIs
Publication statusPublished - 1 Feb 2016
Externally publishedYes

Keywords

  • B cells
  • Ebv transformation
  • Fusion partner
  • Hybridoma
  • Mir transformation
  • Therapeutic antibodies

Fingerprint

Dive into the research topics of 'Updates on the production of therapeutic antibodies using human hybridoma technique'. Together they form a unique fingerprint.

Cite this